Case Study: Educating on Combination Product Access
How a biotech company equipped HCPs to navigate acquisition, coding, and coverage for a dual-therapy regimen.
Case Study: Reimbursement & Market Access — Supporting Products with Required Imaging
How a manufacturer integrated imaging requirements into its access and patient support strategy.
Deal-Driven Policy, Direct-to-Patient Models, and State Momentum: Preparing for 2026
As policy dynamics accelerate across federal and state channels, manufacturers must prepare for multiple scenarios and align internal planning. Key readiness priorities for 2026.
Case Study: Strategic Coding Application Creates a Reimbursement Pathway for a Device Accessory
See how a smarter coding strategy helped a medical device company strengthen payer alignment and accelerate access.
Payer Research: A Strategic Driver of ROI Across the Lifecycle
Design research payers can use: focus on real-world outcomes, durability, and total cost of care; bring payer input in early and often; and pressure-test access levers pre-launch. Turn strong science into coverage, reimbursement, and measurable ROI.
Case Study: Building a Gold-Standard Market Access Framework for a First-in-Class Therapy
See how Magnolia Market Access helped a manufacturer overcome coding gaps, payer unfamiliarity, and site readiness challenges to launch the first FDA-approved therapy in a rare disease — creating a replicable, gold-standard access model.
How 340B Disproportionate Share Hospitals (DSH) are Failing to Reinvest in Patient Care
This issue brief provides insights into how 340B savings are being redirected by covered entities—particularly DSH hospitals—toward financial investments instead of patient care, underscoring the urgency of policy changes to realign the program with its mission.
MFN Policy Executive Order: What It Means for Pricing, Distribution, and Biopharma Strategy
On May 12, 2025, President Trump signed an executive order with the potential to significantly change the U.S. drug pricing and distribution system. Here is what we know about the Administration’s new Most Favored Nation (MFN) policy:
Decoding the 2025 Medicare Shifts: Key Insights for Pharma Market Access with Parker Edman
With the recent release of the 2025 Medicare plan enrollment data, pharma manufacturers must address significant shifts in the Part D prescription drug plan market, that could impact market access, formulary positioning, and patient affordability. We spoke with Parker Edman about the trends, challenges, and what manufacturers should prioritize to stay ahead.
Building a Comprehensive Go-To-Market Strategy Through Stakeholder Ecosystem Mapping
A mid-size client was preparing for a product launch and needed assistance facilitating a successful go-to-market strategy. The company sought to identify and understand the entire stakeholder landscape and create short- and long-term stakeholder engagement strategies to meet the needs of their entire organization.